2019
DOI: 10.21518/2307-1109-2019-1-53-61
|View full text |Cite
|
Sign up to set email alerts
|

Dabigatran and Idaruzizumab. New Opportunities for Improving Patient Safety

Abstract: The widespread use of new oral anticoagulants in clinical practice requires improving the safety of medication use, i.e. the use of specific reversal agents, if necessary. Idarucizumab, a humanied monoclonal antibody fragment, is the first reversal agent authorized in our country that binds to dabigatran. Its efficacy and safety have been validated in several clinical trials, and its use gains experience in real clinical practice.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 29 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?